Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Entamoeba histolytica produces a variety of enzymes crucial for its pathogenesis and survival during amoebiasis. Key targets include cysteine proteases (involved in tissue invasion and cell lysis), amoebapores (pore-forming proteins that disrupt host cell membranes), lipases (implicated in damaging host cells), and a unique cyclooxygenase-like enzyme (which synthesizes prostaglandin E2 for immune modulation). Enzymes involved in L-cysteine synthesis and glycolysis also represent attractive drug targets due to differences from human homologs. Inhibitors targeting these enzymes can potentially block infection with minimal toxicity.
Inhibition of enzymatic activity required for parasite survival and virulence; disruption of tissue invasion, cell lysis, inflammation modulation, and energy production.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Entamoeba histolytica Enzymes (N/A).